Novo Nordisk A/S (NYSE:NVO) Holdings Decreased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,000 shares of the company's stock after selling 20,000 shares during the period. Novo Nordisk A/S makes up approximately 3.2% of Sivik Global Healthcare LLC's holdings, making the stock its 9th biggest holding. Sivik Global Healthcare LLC's holdings in Novo Nordisk A/S were worth $6,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Xponance Inc. lifted its stake in shares of Novo Nordisk A/S by 27.6% in the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company's stock valued at $380,000 after purchasing an additional 576 shares during the last quarter. AQR Capital Management LLC lifted its position in Novo Nordisk A/S by 110.5% in the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company's stock worth $2,450,000 after buying an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Novo Nordisk A/S by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company's stock worth $18,824,000 after buying an additional 2,817 shares during the period. Cetera Investment Advisers raised its stake in shares of Novo Nordisk A/S by 9.5% in the second quarter. Cetera Investment Advisers now owns 290,845 shares of the company's stock valued at $41,515,000 after acquiring an additional 25,307 shares during the period. Finally, New Century Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at $247,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 1.5 %

Novo Nordisk A/S stock traded up $1.30 during mid-day trading on Thursday, reaching $85.33. 5,758,290 shares of the company were exchanged, compared to its average volume of 9,639,824. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The business has a fifty day moving average of $94.32 and a 200 day moving average of $113.82. The firm has a market cap of $382.91 billion, a P/E ratio of 27.61, a PEG ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Buy" and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.